Thyroid dermopathy and acropachy

References

• Bartley GB, Fatourechi V, Kadrmas EF et al. The incidence of Graves’ ophthalmopathy in Olmsted County, Minnesota. Am. J. Ophthalmol.120(4), 511–517 (1995).
   PubMed Web of Science ®Google Scholar
• Bartley GB. The epidemiologic characteristics and clinical course of ophthalmopathy associated with autoimmune thyroid disease in Olmsted County, Minnesota. Trans. Am. Ophthalmol. Soc.92, 477–588 (1994).
   PubMedGoogle Scholar
• Fatourechi V, Bartley GB, Eghbali-Fatourechi GZ, Powell CC, Ahmed DD, Garrity JA. Graves’ dermopathy and acropachy are markers of severe Graves’ ophthalmopathy. Thyroid13(12), 1141–1144 (2003).
   PubMed Web of Science ®Google Scholar
• Bahn RS. Graves’ ophthalmopathy. N. Engl. J. Med.362(8), 726–738 (2010).
   PubMedGoogle Scholar
• Salvi M, De Chiara F, Gardini E et al. Echographic diagnosis of pretibial myxedema in patients with autoimmune thyroid disease. Eur. J. Endocrinol.131(2), 113–119 (1994).
   PubMedGoogle Scholar
• Schwartz KM, Fatourechi V, Ahmed DD, Pond GR. Dermopathy of Graves’ disease (pretibial myxedema): long-term outcome. J. Clin. Endocrinol. Metab.87(2), 438–446 (2002).
   PubMed Web of Science ®Google Scholar
• Missner SC, Ramsay EW, Houck HE et al. Graves’ disease presenting as localized myxedema in a thigh donor graft site. J. Am. Acad. Dermatol.39(5 Pt 2), 846–849 (1998).
   PubMedGoogle Scholar
• Schwartz KM, Ahmed DD, Ahmed I et al. Development of localized myxedema in a skin graft. Int. J. Dermatol.41(7), 401–403 (2002).
   PubMedGoogle Scholar
• Ishii M, Nakagawa K, Hamada T. An ultrastructural study of pretibial myxedema utilizing improved ruthenium red stain. J. Cutan. Pathol.11(2), 125–131 (1984).
   PubMedGoogle Scholar
• Pujol RM, Monmany J, Bague S, Alomar A. Graves’ disease presenting as localized myxoedematous infiltration in a smallpox vaccination scar. Clin. Exp. Dermatol.25(2), 132–134 (2000).
   PubMedGoogle Scholar
• Tong DW, Ho KK. Pretibial myxoedema presenting as a scar infiltrate. Australas. J. Dermatol.39(4), 255–257 (1998).
   PubMedGoogle Scholar
• Wright AL, Buxton PK, Menzies D. Pretibial myxedema localized to scar tissue. Int. J. Dermatol.29(1), 54–55 (1990).
   PubMedGoogle Scholar
• Fatourechi V, Pajouhi M, Fransway AF. Dermopathy of Graves disease (pretibial myxedema): review of 150 cases. Medicine (Baltimore)73(1), 1–7 (1994).
   PubMed Web of Science ®Google Scholar
• Fatourechi V, Ahmed DD, Schwartz KM. Thyroid acropachy: report of 40 patients treated at a single institution in a 26-year period. J. Clin. Endocrinol. Metab.87(12), 5435–5441 (2002).
   PubMed Web of Science ®Google Scholar
• Bahn RS. TSH receptor expression in orbital tissue and its role in the pathogenesis of Graves’ ophthalmopathy. J. Endocrinol. Invest.27(3), 216–220 (2004).
   PubMed Web of Science ®Google Scholar
• Eckstein AK, Johnson KT, Thanos M et al. Current insights into the pathogenesis of Graves’ orbitopathy. Horm. Metab. Res.41(6), 456–464 (2009).
   PubMed Web of Science ®Google Scholar
• Jones SK. Hunter HJA. Skin manifestations of systemic disease. Medicine37(6), 277–281 (2009).
   Google Scholar
• Matsuoka LY, Wortsman J, Uitto J et al. Altered skin elastic fibers in hypothyroid myxedema and pretibial myxedema. Arch. Intern. Med.145(1), 117–121 (1985).
   PubMed Web of Science ®Google Scholar
• Konrad K, Brenner W, Pehamberger H. Ultrastructural and immunological findings in Graves’ disease with pretibial myxedema. J. Cutan. Pathol.7(2), 99–108 (1980).
   PubMedGoogle Scholar
• Fujita H, Asagami C, Suetomi Y et al. Study on the ultrastructure and mucin production in pretibial myxedema. Acta Pathol. Jpn.21(2), 207–230 (1971).
   PubMedGoogle Scholar
• Fatourechi V. Pretibial myxedema: pathophysiology and treatment options. Am. J. Clin. Dermatol.6(5), 295–309 (2005).
   PubMed Web of Science ®Google Scholar
• Heufelder AE, Bahn RS, Scriba PC. Analysis of T-cell antigen receptor variable region gene usage in patients with thyroid-related pretibial dermopathy. J. Invest. Dermatol.105(3), 372–378 (1995).
   PubMedGoogle Scholar
• Somach SC, Helm TN, Lawlor KB et al. Pretibial mucin: histologic patterns and clinical correlation. Arch. Dermatol.129(9), 1152–1156 (1993).
   PubMedGoogle Scholar
• Bull RH, Coburn PR, Mortimer PS. Pretibial myxoedema: a manifestation of lymphoedema? Lancet341(8842), 403–404 (1993).
   PubMedGoogle Scholar
• Rapoport B, Alsabeh R, Aftergood D, McLachlan SM. Elephantiasic pretibial myxedema: insight into and a hypothesis regarding the pathogenesis of the extrathyroidal manifestations of Graves’ disease. Thyroid10(8), 685–692 (2000).
   PubMed Web of Science ®Google Scholar
• Weetman AP. Graves’ disease. N. Engl. J. Med.343(17), 1236–1248 (2000).
   PubMed Web of Science ®Google Scholar
• Ludgate M, Baker G. Unlocking the immunological mechanisms of orbital inflammation in thyroid eye disease. Clin. Exp. Immunol.127(2), 193–198 (2002).
   PubMedGoogle Scholar
• Prabhakar BS, Bahn RS, Smith TJ. Current perspective on the pathogenesis of Graves’ disease and ophthalmopathy. Endocr. Rev.24(6), 802–835 (2003).
   PubMed Web of Science ®Google Scholar
• Gerding MN, van der Meer JW, Broenink M et al. Association of thyrotrophin receptor antibodies with the clinical features of Graves’ ophthalmopathy. Clin. Endocrinol. (Oxf.)52(3), 267–271 (2000).
   PubMed Web of Science ®Google Scholar
• Bartley GB, Fatourechi V, Kadrmas EF et al. Chronology of Graves’ ophthalmopathy in an incidence cohort. Am. J. Ophthalmol.121(4), 426–434 (1996).
   PubMed Web of Science ®Google Scholar
• Cannavo SP, Borgia F, Vaccaro M et al. Pretibial myxoedema associated with Hashimoto’s thyroiditis. J. Eur. Acad. Dermatol. Venereol.16(6), 625–627 (2002).
   PubMed Web of Science ®Google Scholar
• Stewart G, Payne CM, Croft DN. Hashimoto’s thyroiditis associated with dysthyroid eye disease, pretibial myxoedema and thyroid acropachy. J. R. Soc. Med.77(3), 240–243 (1984).
   PubMedGoogle Scholar
• Sarkar D, Singh SK, Bandopadhyaya B, Many MC. Hashimoto’s thyroiditis with ophthalmopathy and dermopathy. J. Assoc. Physicians India45(4), 331–332 (1997).
   PubMedGoogle Scholar
• Ukinç K, Bayraktar M, Gedik A. Hypothyroid Graves’ disease complicated with elephantiasis nostras verrucosa (ENV): a case report and review of the literature. Endocrine36(1), 6–9 (2009).
   PubMedGoogle Scholar
• Bahn RS. Understanding the immunology of Graves’ ophthalmopathy. Is it an autoimmune disease? Endocrinol. Metab. Clin. North Am.29(2), 287–296 (2000).
   PubMed Web of Science ®Google Scholar
• Villanueva R, Inzerillo AM, Tomer Y et al. Limited genetic susceptibility to severe Graves’ ophthalmopathy: no role for CTLA-4 but evidence for an environmental etiology. Thyroid10(9), 791–798 (2000).
   PubMed Web of Science ®Google Scholar
• Smith TJ, Koumas L, Gagnon A et al. Orbital fibroblast heterogeneity may determine the clinical presentation of thyroid-associated ophthalmopathy. J. Clin. Endocrinol. Metab.87(1), 385–392 (2002).
   PubMed Web of Science ®Google Scholar
• Smith TJ, Bahn RS, Gorman CA et al. Stimulation of glycosaminoglycan accumulation by interferon g in cultured human retroocular fibroblasts. J. Clin. Endocrinol. Metab.72(5), 1169–1171 (1991).
   PubMed Web of Science ®Google Scholar
• Gianoukakis AG, Jennings TA, King CS et al. Hyaluronan accumulation in thyroid tissue: evidence for contributions from epithelial cells and fibroblasts. Endocrinology148(1), 54–62 (2007).
   PubMedGoogle Scholar
• Shishiba Y, Imai Y, Odajima R et al. Immunoglobulin G of patients with circumscribed pretibial myxedema of Graves’ disease stimulates proteoglycan synthesis in human skin fibroblasts in culture. Acta Endocrinol. (Copenh.)127(1), 44–51 (1992).
   PubMedGoogle Scholar
• Shishiba Y, Tanaka T, Ozawa Y et al. Chemical characterization of high buoyant density proteoglycan accumulated in the affected skin of pretibial myxedema of Graves’ disease. Endocrinol. Jpn.33(3), 395–403 (1986).
   PubMedGoogle Scholar
• Kahaly G, Forster G, Hansen C. Glycosaminoglycans in thyroid eye disease. Thyroid8(5), 429–432 (1998).
   PubMedGoogle Scholar
• Hofbauer LC, Muhlberg T, Konig A et al. Soluble interleukin-1 receptor antagonist serum levels in smokers and nonsmokers with Graves’ ophthalmopathy undergoing orbital radiotherapy. J. Clin. Endocrinol. Metab.82(7), 2244–2247 (1997).
   PubMedGoogle Scholar
• Tiu SC, Choi CH. Elephantiasic thyroid dermopathy. Hong Kong Med. J.12(2), 159–160 (2006).
   PubMedGoogle Scholar
• Heufelder AE. T-cell restriction in thyroid eye disease. Thyroid8(5), 419–422 (1998).
   PubMedGoogle Scholar
• Heufelder AE, Dutton CM, Sarkar G et al. Detection of TSH receptor RNA in cultured fibroblasts from patients with Graves’ ophthalmopathy and pretibial dermopathy. Thyroid3(4), 297–300 (1993).
   PubMed Web of Science ®Google Scholar
• Bahn RS, Dutton CM, Natt N et al. Thyrotropin receptor expression in Graves’ orbital adipose/connective tissues: potential autoantigen in Graves’ ophthalmopathy. J. Clin. Endocrinol. Metab.83(3), 998–1002 (1998).
   PubMed Web of Science ®Google Scholar
• Daumerie C, Ludgate M, Costagliola S, Many MC. Evidence for thyrotropin receptor immunoreactivity in pretibial connective tissue from patients with thyroid-associated dermopathy. Eur. J. Endocrinol.146(1), 35–38 (2002).
   PubMed Web of Science ®Google Scholar
• Stadlmayr W, Spitzweg C, Bichlmair AM et al. TSH receptor transcripts and TSH receptor-like immunoreactivity in orbital and pretibial fibroblasts of patients with Graves’ ophthalmopathy and pretibial myxedema. Thyroid7(1), 3–12 (1997).
   PubMedGoogle Scholar
• Metcalfe R, Jordan N, Watson P et al. Demonstration of immunoglobulin G, A, and E autoantibodies to the human thyrotropin receptor using flow cytometry. J. Clin. Endocrinol. Metab.87(4), 1754–1761 (2002).
   PubMed Web of Science ®Google Scholar
• Cianfarani F, Baldini E, Cavalli A et al. TSH receptor and thyroid-specific gene expression in human skin. J. Invest. Dermatol.130(1), 93–101 (2010).
   PubMed Web of Science ®Google Scholar
• Heufelder AE, Schworm HD, Wenzel BE et al. Molecular analysis of antigen receptor variable region repertoires in T lymphocytes infiltrating the intrathyroidal and extrathyroidal manifestations in patients with Graves’ disease. Exp. Clin. Endocrinol. Diabetes104(Suppl. 4), 84–87 (1996).
   PubMedGoogle Scholar
• Douglas RS, Naik V, Hwang CJ et al. B cells from patients with Graves’ disease aberrantly express the IGF-1 receptor: implications for disease pathogenesis. J. Immunol.181(8), 5768–5774 (2008).
   PubMed Web of Science ®Google Scholar
• Weightman DR, Perros P, Sherif IH et al. Autoantibodies to IGF-1 binding sites in thyroid associated ophthalmopathy. Autoimmunity16(4), 251–257 (1993).
   PubMed Web of Science ®Google Scholar
• Wu SL, Chang TC, Chang TJ et al. Cloning and sequencing of complete thyrotropin receptor transcripts in pretibial fibroblast culture cells. J. Endocrinol. Invest.19(6), 365–370 (1996).
   PubMedGoogle Scholar
• Bahn RS. Clinical review 157: Pathophysiology of Graves’ ophthalmopathy: the cycle of disease. J. Clin. Endocrinol. Metab.88(5), 1939–1946 (2003).
   PubMed Web of Science ®Google Scholar
• Tokuda Y, Kawachi S, Murata H et al. Chronic obesity lymphoedematous mucinosis: three cases of pretibial mucinosis in obese patients with pitting oedema. Br. J. Dermatol.154(1), 157–161 (2006).
   PubMedGoogle Scholar
• Solberg Y, Rosner M, Belkin M. The association between cigarette smoking and ocular diseases. Surv. Ophthalmol.42(6), 535–547 (1998).
   PubMed Web of Science ®Google Scholar
• Shine B, Fells P, Edwards OM et al. Association between Graves’ ophthalmopathy and smoking. Lancet335(8700), 1261–1263 (1990).
   PubMed Web of Science ®Google Scholar
• Bertelsen JB, Hegedus L. Cigarette smoking and the thyroid. Thyroid4(3), 327–331 (1994).
   PubMed Web of Science ®Google Scholar
• Mack WP, Stasior GO, Cao HJ et al. The effect of cigarette smoke constituents on the expression of HLA-DR in orbital fibroblasts derived from patients with Graves ophthalmopathy. Ophthal. Plast. Reconstr. Surg.15(4), 260–271 (1999).
   PubMed Web of Science ®Google Scholar
• Tallstedt L, Lundell G, Taube A. Graves’ ophthalmopathy and tobacco smoking. Acta Endocrinol. (Copenh.)129(2), 147–150 (1993).
   PubMedGoogle Scholar
• Pfeilschifter J, Ziegler R. Smoking and endocrine ophthalmopathy: impact of smoking severity and current vs lifetime cigarette consumption. Clin. Endocrinol. (Oxf.)45(4), 477–481 (1996).
   PubMed Web of Science ®Google Scholar
• Fiore MC, Jaen CR. A clinical blueprint to accelerate the elimination of tobacco use. JAMA299(17), 2083–2085 (2008).
   PubMedGoogle Scholar
• Hegedius L, Brix TH, Vestergaard P. Relationship between cigarette smoking and Graves’ ophthalmopathy. J. Endocrinol. Invest.27(3), 265–271 (2004).
   PubMed Web of Science ®Google Scholar
• Krassas GE, Gogakos A. Thyroid-associated ophthalmopathy in juvenile Graves’ disease: clinical, endocrine and therapeutic aspects. J. Pediatr. Endocrinol. Metab.19(10), 1193–1206 (2006).
   PubMedGoogle Scholar
• Krassas GE, Perros P. Prevention of thyroid associated-ophthalmopathy in children and adults: current views and management of preventable risk factors. Pediatr. Endocrinol. Rev.4(3), 218–224 (2007).
   PubMedGoogle Scholar
• Thornton J, Kelly SP, Harrison RA et al. Cigarette smoking and thyroid eye disease: a systematic review. Eye (Lond.)21(9), 1135–1345 (2007).
   PubMed Web of Science ®Google Scholar
• van der Heide F, Dijkstra A, Weersma RK et al. Effects of active and passive smoking on disease course of Crohn’s disease and ulcerative colitis. Inflamm. Bowel Dis.15(8), 1199–1207 (2009).
   PubMed Web of Science ®Google Scholar
• Bartalena L, Marcocci C, Tanda ML et al. Cigarette smoking and treatment outcomes in Graves ophthalmopathy. Ann. Intern. Med.129(8), 632–635 (1998).
   PubMed Web of Science ®Google Scholar
• Jaume JC, Prummel MF, Wiersinga WM et al. Thyrotropin receptor autoantibodies recognizing two different epitopes on the TSH receptor: lack of relationship to patient age, sex, and ophthalmopathy. Thyroid3(4), 291–295 (1993).
   PubMedGoogle Scholar
• Fatourechi MM, Fatourechi V. Association of tobacco use with thyroid dermopathy. Presented at: 12th Annual Meeting of the American Association of Clinical Endocrinologists (AACE). San Diego, CA, USA, 14 May, 2003.
   Google Scholar
• Bartley GB, Fatourechi V, Kadrmas EF et al. Clinical features of Graves’ ophthalmopathy in an incidence cohort. Am. J. Ophthalmol.121(3), 284–290 (1996).
   PubMed Web of Science ®Google Scholar
• Fatourechi V, Garrity JA, Bartley GB et al. Orbital decompression in Graves’ ophthalmopathy associated with pretibial myxedema. J. Endocrinol. Invest.16(6), 433–437 (1993).
   PubMedGoogle Scholar
• Georgala S, Katoulis AC, Georgala C et al. Pretibial myxedema as the initial manifestation of Graves’ disease. J. Eur. Acad. Dermatol. Venereol.16(4), 380–383 (2002).
   PubMedGoogle Scholar
• Omohundro C, Dijkstra JW, Camisa C, Bergfeld WF. Early onset pretibial myxedema in the absence of ophthalmopathy: a morphologic evolution. Cutis58(3), 211–214 (1996).
   PubMedGoogle Scholar
• Wiersinga WM, Bartalena L. Epidemiology and prevention of Graves’ ophthalmopathy. Thyroid12(10), 855–860 (2002).
   PubMed Web of Science ®Google Scholar
• Garrity JA, Fatourechi V, Bergstralh EJ et al. Results of transantral orbital decompression in 428 patients with severe Graves’ ophthalmopathy. Am. J. Ophthalmol.116(5), 533–547 (1993).
   PubMed Web of Science ®Google Scholar
• Curti LG, Siccardi M, Santianello EB et al. Full-blown hypothyroidism associated with vitiligo and acropachy: report of one case. Thyroidology4(3), 111–114 (1992).
   PubMedGoogle Scholar
• Mourits MP. Prevention of Graves’ orbitopathy: early diagnosis of thyroid-associated orbitopathy in Graves’ disease. Orbit27(6), 399–400 (2008).
   PubMedGoogle Scholar
• Mourits MP, Koornneef L, Wiersinga WM et al. Clinical criteria for the assessment of disease activity in Graves’ ophthalmopathy: a novel approach. Br. J. Ophthalmol.73(8), 639–644 (1989).
   PubMed Web of Science ®Google Scholar
• Gleeson H, Kelly W, Toft A et al. Severe thyroid eye disease associated with primary hypothyroidism and thyroid-associated dermopathy. Thyroid9(11), 1115–1118 (1999).
   PubMed Web of Science ®Google Scholar
• Katsambas A, Pantazi V, Giannakopoulou H, Potouridou I. Localized myxedema in Grave’s disease confined to the toes. Int. J. Dermatol.39(12), 953–954 (2000).
   PubMedGoogle Scholar
• Kato N, Ueno H, Matsubara M. A case report of EMO syndrome showing localized hyperhidrosis in pretibial myxedema. J. Dermatol.18(10), 598–604 (1991).
   PubMedGoogle Scholar
• Siegler M, Refetoff S. Pretibial myxedema: a reversible cause of foot drop due to entrapment of the peroneal nerve. N. Engl J. Med.294(25), 1383–1384 (1976).
   PubMedGoogle Scholar
• Batal O, Hatem SF. Radiologic case study: thyroid acropachy. Orthopedics31(1), 2, 98–100 (2008).
   PubMedGoogle Scholar
• del-Rio E, Velez A, Sanchez Yus E. Persistent asymptomatic nodules on the legs: nodular pretibial myxedema. Arch. Dermatol.129(3), 365–366, 368–369 (1993).
   PubMedGoogle Scholar
• Hunzeker CM, Kamino H, Walters RF, Kovich OI. Nodular pretibial myxedema. Dermatol. Online J.14(10), 8 (2008).
   PubMedGoogle Scholar
• Singh SP, Ellyin F, Singh SK et al. Elephantiasis-like appearance of upper and lower extremities in Graves’ dermopathy. Am. J. Med. Sci.290(2), 73–76 (1985).
   PubMed Web of Science ®Google Scholar
• Terheyden P, Kahaly GJ, Zillikens D et al. Lack of response of elephantiasic pretibial myxoedema to treatment with high-dose intravenous immunoglobulins. Clin. Exp. Dermatol.28(2), 224–246 (2003).
   PubMedGoogle Scholar
• Sharma VK, Sood A, Sood A, Singh MK. Elephantiasic pretibial myxedema in Graves’ disease. J. Assoc. Physicians India50, 1430–1431 (2002).
   PubMedGoogle Scholar
• Susser WS, Heermans AG, Chapman MS et al. Elephantiasic pretibial myxedema: a novel treatment for an uncommon disorder. J. Am. Acad. Dermatol.46(5), 723–726 (2002).
   PubMed Web of Science ®Google Scholar
• Bilen H, Atasoy M, Akcay G et al. Elephantiasic pretibial myxedema and cutis verticis gyrata caused by Graves’ disease. Thyroid16(8), 815–816 (2006).
   PubMedGoogle Scholar
• Cohen JB, Balzer B, Wapnir I et al. Elephantiasic pretibial myxedema. Thyroid14(3), 237–238 (2004).
   PubMedGoogle Scholar
• Jowkar F, Sari Aslani F. Elephantiasic pretibial myxedema. J. Pakistan Assoc. Dermatol.17(3), 187–189 (2007).
   Google Scholar
• Rotman-Pikielny P, Brucker-Davis F, Turner ML, Sarlis NJ, Skarulis MC. Lack of effect of long-term octreotide therapy in severe thyroid-associated dermopathy. Thyroid13(5), 465–470 (2003).
   PubMedGoogle Scholar
• Akasu F, Takazawa K, Akasu R et al. Localized myxedema on the nasal dorsum in a patient with Graves’ disease: report of a case. J. Endocrinol. Invest.12(10), 717–721 (1989).
   PubMedGoogle Scholar
• Noppakun N, Bancheun K, Chandraprasert S. Unusual locations of localized myxedema in Graves’ disease: report of three cases. Arch. Dermatol.122(1), 85–88 (1986).
   PubMedGoogle Scholar
• Rice SA, Peden NR, McGlynn S, Morton C. Atypical presentation of infiltrative thyroid dermopathy. Clin. Exp. Dermatol.35(1), 56–58 (2010).
   PubMedGoogle Scholar
• Davies TF. Trauma and pressure explain the clinical presentation of the Graves’ disease triad. Thyroid10(8), 629–630 (2000).
   PubMed Web of Science ®Google Scholar
• Kundu AK. Correlation between clubbing and exophthalmos and/or pretibial myxoedema in Graves disease. J. Assoc. Physicians India47(4), 462 (1999).
   Google Scholar
• Vanhoenacker FM, Pelckmans MC, De Beuckeleer LH et al. Thyroid acropachy: correlation of imaging and pathology. Eur. Radiol.11(6), 1058–1062 (2001).
   PubMedGoogle Scholar
• Romano TJ. Other soft tissue pain conditions. J. Musculoskeletal Pain14(1), 65–71 (2006).
   Google Scholar
• Anderson CK, Miller OF 3rd. Triad of exophthalmos, pretibial myxedema, and acropachy in a patient with Graves’ disease. J. Am. Acad. Dermatol.48(6), 970–972 (2003).
   PubMed Web of Science ®Google Scholar
• Capsoni F, Minonzio F, Sarzi-Puttini P et al. Thyroid acropachy: an unusual rheumatic manifestation of Graves’ disease. Clin. Exp. Rheumatol.23(1), 125–126 (2005).
   PubMedGoogle Scholar
• Asai S, Asada K, Miyachi H. Clubbed fingers in a patient with inflammatory gingival hyperplasia. Intern. Med.44(12), 1307–1311 (2005).
   PubMedGoogle Scholar
• Tran HA. Thyroid acropachy. Intern. Med. J.34(8), 513–514 (2004).
   PubMedGoogle Scholar
• Galinat S, Archambeaud F, Fronty S et al. Thyroid acropachy after radioiodine therapy. Endocr. J.47(Suppl.), 116 (2000).
   Google Scholar
• Rothschild BM, Yoon BH. Thyroid acropachy complicated by lymphatic obstruction. Arthritis Rheum.25(5), 588–590 (1982).
   PubMedGoogle Scholar
• Goette DK. Thyroid acropachy. Arch. Dermatol.116(2), 205–206 (1980).
   PubMedGoogle Scholar
• Kinsella RA Jr, Back DK. Thyroid acropachy. Med. Clin. North Am.52(2), 393–398 (1968).
   PubMedGoogle Scholar
• Seigel RS, Thrall JH, Sisson JC. 99mTc-pyrophosphate scan and radiographic correlation in thyroid acropachy: case report. J. Nucl. Med.17(9), 791–793 (1976).
   PubMed Web of Science ®Google Scholar
• Kureshi F, Davis MD, Burkemper NM, Weenig RH, Pittelkow MR, Gamble GL. Thyroid dermopathy: an underrecognized cause of leg edema. Cutis79(3), 219–224 (2007).
   PubMedGoogle Scholar
• Morris JC 3rd, Hay ID, Nelson RE et al. Clinical utility of thyrotropin-receptor antibody assays: comparison of radioreceptor and bioassay methods. Mayo Clin. Proc.63(7), 707–717 (1988).
   PubMed Web of Science ®Google Scholar
• Imgrund M, Warnatz K, Uhl M et al. EMO syndrome as a late explanation for pretibial swelling. Rheumatology (Oxf.)40(3), 357–358 (2001).
   PubMedGoogle Scholar
• Ogrin C. Increased bone alkaline phosphatase and isolated subcortical bone uptake of technetium-99m hydroxymethylene diphosphonate in the lower extremities in a patient with Graves’ disease: a distinctly unusual variant of Graves’ acropachy. Thyroid18(11), 1227–1229 (2008).
   PubMedGoogle Scholar
• McNeill AM, Barr RJ. Scleromyxedema-like fibromucinosis in a patient undergoing hemodialysis. Int. J. Dermatol.41(6), 364–367 (2002).
   PubMedGoogle Scholar
• Poswig A, Hinrichs R, Megahed M et al. Discrete papular mucinosis: a rare subtype of lichen myxoedematosus. Clin. Exp. Dermatol.25(4), 289–292 (2000).
   PubMedGoogle Scholar
• Harris JE, Purcell SM, Griffin TD. Acral persistent papular mucinosis. J. Am. Acad. Dermatol.51(6), 982–988 (2004).
   PubMedGoogle Scholar
• Kim KJ, Kim HH, Chang SE et al. A case of pretibial mucinosis without thyroid disease. J. Dermatol.29(6), 383–385 (2002).
   PubMedGoogle Scholar
• Rongioletti F. Scleromyxedema: a potentially disabling and fatal disease. G. Ital. Dermatol. Venereol.135(5), 323–328 (2000).
   Google Scholar
• Lo PY, Tzung TY. Lichen myxedematosus in a patient with hepatocellular carcinoma. Br. J. Dermatol.143(2), 452–453 (2000).
   PubMedGoogle Scholar
• Yamazaki S, Katayama I, Satoh T et al. Acral ichthyosiform mucinosis in association with Sjögren’s syndrome: a peculiar form of pretibial myxedema? J. Dermatol.20(11), 715–718 (1993).
   PubMedGoogle Scholar
• Jackson EM, English JC 3rd. Diffuse cutaneous mucinoses. Dermatol. Clin.20(3), 493–501 (2002).
   PubMedGoogle Scholar
• Kulczycki A, Nelson M, Eisen A, Heffernan M. Scleromyxoedema: treatment of cutaneous and systemic manifestations with high-dose intravenous immunoglobulin. Br. J. Dermatol.149(6), 1276–1281 (2003).
   PubMed Web of Science ®Google Scholar
• Rongioletti F, Donati P, Amantea A et al. Obesity-associated lymphoedematous mucinosis. J. Cutan. Pathol.36(10), 1089–1094 (2009).
   PubMedGoogle Scholar
• Mackay-Wiggan JM, Cohen DJ, Hardy MA, Knobler EH, Grossman ME. Nephrogenic fibrosing dermopathy (scleromyxedema-like illness of renal disease). J. Am. Acad. Dermatol.48(1), 55–60 (2003).
   PubMed Web of Science ®Google Scholar
• Streams BN, Liu V, Liegeois N et al. Clinical and pathologic features of nephrogenic fibrosing dermopathy: a report of two cases. J. Am. Acad. Dermatol.48(1), 42–47 (2003).
   PubMed Web of Science ®Google Scholar
• Chung HJ, Chung KY. Nephrogenic fibrosing dermopathy: response to high-dose intravenous immunoglobulin. Br. J. Dermatol.150(3), 596–597 (2004).
   PubMed Web of Science ®Google Scholar
• Lister RK, Jolles S, Whittaker S et al. Scleromyxedema: response to high-dose intravenous immunoglobulin (hdIVIg). J. Am. Acad. Dermatol.43(2 Pt 2), 403–408 (2000).
   PubMed Web of Science ®Google Scholar
• Tallstedt L, Lundell G, Blomgren H et al. Does early administration of thyroxine reduce the development of Graves’ ophthalmopathy after radioiodine treatment? Eur. J. Endocrinol.130(5), 494–497 (1994).
   PubMed Web of Science ®Google Scholar
• Bartalena L, Marcocci C, Lai A et al. Graves’ hyperthyroidism of recent onset and Graves’ orbitopathy: to ablate or not to ablate the thyroid? J. Endocrinol. Invest.31(6), 578–581 (2008).
   PubMedGoogle Scholar
• Bartalena L, Tanda ML, Piantanida E et al. Relationship between management of hyperthyroidism and course of the ophthalmopathy. J. Endocrinol. Invest.27(3), 288–294 (2004).
   PubMed Web of Science ®Google Scholar
• Bartalena L, Wiersinga WM, Pinchera A. Graves’ ophthalmopathy: state of the art and perspectives. J. Endocrinol. Invest.27(3), 295–301 (2004).
   PubMedGoogle Scholar
• Tallstedt L, Lundell G. Radioiodine treatment, ablation, and ophthalmopathy: a balanced perspective. Thyroid7(2), 241–245 (1997).
   PubMedGoogle Scholar
• Tallstedt L, Lundell G, Torring O et al; The Thyroid Study Group. Occurrence of ophthalmopathy after treatment for Graves’ hyperthyroidism. N. Engl. J. Med.326(26), 1733–1738 (1992).
   PubMed Web of Science ®Google Scholar
• Bartalena L, Marcocci C, Bogazzi F et al. Relation between therapy for hyperthyroidism and the course of Graves’ ophthalmopathy. N. Engl. J. Med.338(2), 73–78 (1998).
   PubMed Web of Science ®Google Scholar
• Perros P, Kendall-Taylor P, Neoh C et al. A prospective study of the effects of radioiodine therapy for hyperthyroidism in patients with minimally active Graves’ ophthalmopathy. J. Clin. Endocrinol. Metab.90(9), 5321–5323 (2005).
   PubMed Web of Science ®Google Scholar
• DeGroot LJ. Radioiodine and the immune system. Thyroid7(2), 259–264 (1997).
   PubMed Web of Science ®Google Scholar
• Menconi F, Marino M, Pinchera A et al. Effects of total thyroid ablation versus near-total thyroidectomy alone on mild to moderate Graves’ orbitopathy treated with intravenous glucocorticoids. J. Clin. Endocrinol. Metab.92(5), 1653–1658 (2007).
   PubMed Web of Science ®Google Scholar
• Vana S, Nemec J, Rezek P et al. Treatment of endocrine orbital disease by elimination of the thyroid gland: the effect of unsuccessful elimination, severe pretibial myxedema and persistence of hypothyroidism after removal in long-term results. Vnitr. Lek.44(7), 387–390 (1998).
   PubMedGoogle Scholar
• Moleti M, Mattina F, Salamone I et al. Effects of thyroidectomy alone or followed by radioiodine ablation of thyroid remnants on the outcome of Graves’ ophthalmopathy. Thyroid13(7), 653–658 (2003).
   PubMedGoogle Scholar
• Bartalena L, Marcocci C, Tanda ML et al. An update on medical management of Graves’ ophthalmopathy. J. Endocrinol. Invest.28(5), 469–478 (2005).
   PubMedGoogle Scholar
• Bartalena L, Pinchera A, Marcocci C. Management of Graves’ ophthalmopathy: reality and perspectives. Endocr. Rev.21(2), 168–199 (2000).
   PubMed Web of Science ®Google Scholar
• Kriss JP. Pathogenesis and treatment of pretibial myxedema. Endocrinol. Metab. Clin. North Am.16(2), 409–415 (1987).
   PubMed Web of Science ®Google Scholar
• Kriss JP, Pleshakov V, Rosenblum A et al. Therapy with occlusive dressings of pretibial myxedema with fluocinolone acetonide. J. Clin. Endocrinol. Metab.27(5), 595–604 (1967).
   PubMedGoogle Scholar
• Volden G. Successful treatment of chronic skin diseases with clobetasol propionate and a hydrocolloid occlusive dressing. Acta Derm. Venereol.72(1), 69–71 (1992).
   PubMed Web of Science ®Google Scholar
• Parker LN, Wu SY, Lai MK et al. The early diagnosis of atypical thyroid acropachy. Arch. Intern. Med.142(9), 1749–1751 (1982).
   PubMedGoogle Scholar
• Engin B, Gumusel M, Ozdemir M et al. Successful combined pentoxifylline and intralesional triamcinolone acetonide treatment of severe pretibial myxedema. Dermatol. Online J.13(2), 16 (2007).
   PubMedGoogle Scholar
• Lang PG, Sisson JC, Lynch PJ. Intralesional triamcinolone therapy for pretibial myxedema. Arch. Dermatol.111(2), 197–202 (1975).
   PubMedGoogle Scholar
• Pingsmann A, Ockenfels HM, Patsalis T. Surgical excision of pseudotumorous pretibial myxedema. Foot Ankle Int.17(2), 107–110 (1996).
   PubMedGoogle Scholar
• Shaw SJ, Kamdar V, Bughi S. Elephantiasic form of severe pseudotumorous pretibial myxedema: a case report. Endocrinologist10, 433–436 (2000).
   Google Scholar
• Felton J, Derrick EK, Price ML. Successful combined surgical and octreotide treatment of severe pretibial myxoedema reviewed after 9 years. Br. J. Dermatol.148(4), 825–826 (2003).
   PubMedGoogle Scholar
• Derrick EK, Tanner B, Price ML. Successful surgical treatment of severe pretibial myxoedema. Br. J. Dermatol.133(2), 317–318 (1995).
   PubMed Web of Science ®Google Scholar
• Noppen M, Velkeniers B, Steenssens L, Vanhaelst L. Beneficial effects of plasmapheresis followed by immunosuppressive therapy in pretibial myxedema. Acta Clin. Belg.43(5), 381–383 (1988).
   PubMed Web of Science ®Google Scholar
• Kuzuya N, DeGroot LJ. Effect of plasmapheresis and steroid treatment on thyrotropin binding inhibitory immunoglobulins in a patient with exophthalmos and a patient with pretibial myxedema. J. Endocrinol. Invest.5(6), 373–378 (1982).
   PubMed Web of Science ®Google Scholar
• Dandona P, Marshall N, Bidey S, Nathan AW, Havard CW. Exophthalmos and pretibial myxoedema not responding to plasmapheresis. Br. Med. J.2(6191), 667–668 (1979).
   PubMedGoogle Scholar
• Lewis RA, Slater N, Croft DN. Exophthalmos and pretibial myxoedema not responding to plasmapheresis. Br. Med. J.2(6186), 390–391 (1979).
   PubMedGoogle Scholar
• Kriss JP. Treatment of exophthalmos and pretibial myxoedema with plasmapheresis. Br. Med. J.1(6171), 1149–1150 (1979).
   PubMedGoogle Scholar
• Dandona P, Marshall NJ, Bidey SP et al. Successful treatment of exophthalmos and pretibial myxoedema with plasmapheresis. Br. Med. J.1(6160), 374–376 (1979).
   PubMedGoogle Scholar
• Antonelli A, Navarranne A, Palla R et al. Pretibial myxedema and high-dose intravenous immunoglobulin treatment. Thyroid4(4), 399–408 (1994).
   PubMed Web of Science ®Google Scholar
• Kuyvenhoven JP, van der Pijl JW, Goslings BM et al. Graves’ dermopathy: does octreotide scintigraphy predict the response to octreotide treatment? Thyroid6(5), 385–389 (1996).
   PubMedGoogle Scholar
• Marcocci C, Marino M, Rocchi R et al. Novel aspects of immunosuppressive and radiotherapy management of Graves’ ophthalmopathy. J. Endocrinol. Invest.27(3), 272–280 (2004).
   PubMedGoogle Scholar
• Wemeau JL, Caron P, Beckers A et al. Octreotide (long-acting release formulation) treatment in patients with Graves’ orbitopathy: clinical results of a four-month, randomized, placebo-controlled, double-blind study. J. Clin. Endocrinol. Metab.90(2), 841–848 (2005).
   PubMed Web of Science ®Google Scholar
• Dickinson AJ, Vaidya B, Miller M et al. Double-blind, placebo-controlled trial of octreotide long-acting repeatable (LAR) in thyroid-associated ophthalmopathy. J. Clin. Endocrinol. Metab.89(12), 5910–5915 (2004).
   PubMed Web of Science ®Google Scholar
• Banga JP, Nielsen CH, Gilbert JA et al. Application of new therapies in Graves’ disease and thyroid-associated ophthalmopathy: animal models and translation to human clinical trials. Thyroid18(9), 973–981 (2008).
   PubMedGoogle Scholar
• El Fassi D, Banga JP, Gilbert JA et al. Treatment of Graves’ disease with rituximab specifically reduces the production of thyroid stimulating autoantibodies. Clin. Immunol.130(3), 252–258 (2009).
   PubMed Web of Science ®Google Scholar
• Vannucchi G, Campi I, Bonomi M et al. Rituximab treatment in patients with active Graves’ orbitopathy: effects on proinflammatory and humoral immune reactions. Clin. Exp. Immunol.161(3), 436–443 (2010).
   PubMed Web of Science ®Google Scholar
• Heemstra KA, Toes RE, Sepers J et al. Rituximab in relapsing Graves’ disease: a phase II study. Eur. J. Endocrinol.159(5), 609–615 (2008).
   PubMed Web of Science ®Google Scholar
• Salvi M, Vannucchi G, Campi I et al. Rituximab treatment in a patient with severe thyroid-associated ophthalmopathy: effects on orbital lymphocytic infiltrates. Clin. Immunol.131(2), 360–365 (2009).
   PubMed Web of Science ®Google Scholar
• Salvi M, Vannucchi G, Campi I et al. New immunomodulators in the treatment of Graves’ ophthalmopathy. Ann. Endocrinol. (Paris)69(2), 153–156 (2008).
   PubMed Web of Science ®Google Scholar
• Salvi M, Vannucchi G, Campi I et al. Treatment of Graves’ disease and associated ophthalmopathy with the anti-CD20 monoclonal antibody rituximab: an open study. Eur. J. Endocrinol.156(1), 33–40 (2007).
   PubMed Web of Science ®Google Scholar
• Fatourechi V. Pretibial myxedema (thyroid dermopathy). In: Thyroid Disorders With Cutaneous Manifestations. Heymann WR (Ed.). Springer-Verlag London Limited, London, UK, 103–119 (2008).
   Google Scholar